CTOs on the Move

Southwest Health Systems

www.smrmc.com

 
Southwest Mississippi Regional Medical Center (SMRMC) in McComb, Mississippi was established in 1969, and serves a seven-county area of Mississippi. SMRMC also draws from two parishes in neighboring eastern Louisiana. According to the most recent
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.smrmc.com
  • 215 Marion Ave
    Mccomb, MS USA 39648
  • Phone: 601.249.5500

Executives

Name Title Contact Details

Similar Companies

Center for Family Health

The Center for Family Health is an independent, federally qualified health center, providing primary medical care and dental services to Jackson County residents regardless of ability to pay. A patient-centered medical home, the Center has been serving the community since 1991. Today, it operates a main facility, four school health centers and a satellite clinic at LifeWays, the community mental health agency.

Houck Limited

Houck Limited is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alcohol Research Group

Alcohol Research Group is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trinity Communications

Trinity Communications is a Media, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthetic Biologics

Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.